DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Eli Lilly - 2 Taltz - 2 Lilly - 1 tirzepatide - 1 Lilly's Taltz - 1 Alex Thompson - 1 Leroy Leo - 1 Khushi - 1
Top related locs:
Indianapolis Bengaluru Francisco
Top related orgs:
Dice Therapeutics - 2 U.S . Federal Trade Commission - 1 Pharmaceuticals - 1 Thomson - 1

Search resuls for: "Taltz"


3 mentions found


☆ Eli Lilly to buy immunology drug developer Dice for $2.4 billion
  + stars: | 2023-06-20 | by ( ) www.reuters.com   time to read: +2 min
June 20 (Reuters) - Eli Lilly and Co (LLY.N) agreed to buy Dice Therapeutics Inc (DICE.O) for about $2.4 billion in cash on Tuesday, bolstering its immune disease-related portfolio with a largely oral drug developer. Dice's lead drug DC-806, which is currently in a mid-stage trial, is an immunology drug for a skin condition called psoriasis and other diseases. Indianapolis-headquartered Lilly is focusing on immunology to drive future growth, along with a widely expected approval of obesity drug candidate tirzepatide. Lilly has offered Dice $48 per share in cash, a premium of about 42% to the stock's last close. Lilly's Taltz garnered $2.48 billion in 2022 while its other immunology drug Olumiant generated $830.5 million in sales.
Persons: Eli Lilly, Taltz, Lilly, tirzepatide, Lilly's Taltz, Alex Thompson, Leroy Leo, Khushi, Sriraj Organizations: Dice Therapeutics, U.S . Federal Trade Commission, Pharmaceuticals, Thomson Locations: Indianapolis, Bengaluru
☆ Eli Lilly to acquire Dice Therapeutics for $2.4 billion in autoimmune treatment push
  + stars: | 2023-06-20 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +1 min
Eli Lilly on Tuesday said it struck a $2.4 billion deal to acquire Dice Therapeutics in a bid to bulk up its treatment portfolio for immune-related diseases. Dice Therapeutics' share price jumped more than 37% to just under the purchase price. Auto-immune diseases can causes pain, fatigue, dizziness, depression and rashes, among other symptoms. There are more than 100 known autoimmune diseases, including lupus, rheumatoid arthritis, Crohn's disease and ulcerative colitis. Eli Lilly's immunology portfolio includes drugs like Taltz, which treats plaque psoriasis, and Olumiant, a treatment for rheumatoid arthritis.
Persons: Eli Lilly, Eli Lilly's, Patrik Jonsson, Eli, Taltz Organizations: Dice Therapeutics Locations: Francisco
☆ Eli Lilly is still best long-term growth story in large cap pharma despite messy quarter
  + stars: | 2022-11-01 | by ( Jeff Marks | ) www.cnbc.com   time to read: +10 min
Eli Lilly (LLY) reported a noisy third-quarter before the opening bell Thursday, but the numbers did not change our thesis in what we think is the best long-term growth story in large cap pharma. On the bottom line, Eli Lilly grew its adjusted earnings-per-share by 12% to $1.98, beating the consensus forecast of $1.92, according to Refinitiv. Bottom line Another messy quarter for Eli Lilly but one that has little impact on what we believe is still a compelling story. Verzenio revenue of $618 million beat estimates of $615 million Jardiance revenue of $573 million beat estimates of $495 million Taltz revenue of $679 million missed estimates of $682 million Retevmo revenue of $40.5 million missed estimates of $52 million. This Tuesday, July 17, 2012, photo shows the Eli Lilly corporate headquarters in Indianapolis.
0 next >>
Total: 3